98%
921
2 minutes
20
Background: The number of total pancreatectomy cases have increased worldwide, expanding the need for new insulin products and high-titer pancrelipases. However, the current data that is focused on hypoglycemic events after a total pancreatectomy from large nationwide series are still lacking. This study is aimed to assess the risk factors associated with hypoglycemic events after a total pancreatectomy.
Methods: Data were prospectively collected from 216 consecutive patients who underwent total pancreatectomies between August 2015 and December 2017 from 68 Japanese centers. Of the 216 patients, 166 with a follow-up period of 1 year were analyzed. The risk factors for hypoglycemic events at 6 and 12 months (postoperative months 6 and 12) were investigated based on the results of a nationwide multicenter prospective study.
Results: Of the 166 patients, 57 (34%) and 70 (42%) experienced moderate or severe hypoglycemic events or hypoglycemia unawareness on a monthly basis at postoperative months 6 and 12, respectively. Multivariate analysis revealed that body weight loss after surgery ≥0.3 kg and total cholesterol level ≤136 mg/dL at postoperative month 6, and glycated hemoglobin level ≤8.9% and rapid-acting insulin use at postoperative month 12 were independent risk factors for hypoglycemic events after a total pancreatectomy. There were different independent risk factors depending on the postoperative period.
Conclusion: Patients with body weight loss after surgery, low total cholesterol level, strict glycemic control, and using rapid-acting insulin should be aware of the occurrence of hypoglycemic events after their total pancreatectomy. In order to prevent hypoglycemic events after a total pancreatectomy, we need to consider optimal nutritional and glycemic control according to the postoperative period.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.surg.2022.04.031 | DOI Listing |
JAMA Netw Open
September 2025
Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
Importance: The cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may vary by body mass index (BMI), but evidence on BMI-specific outcomes remains limited.
Objective: To investigate the associations of GLP-1 RA use with cardiovascular and kidney outcomes across BMI categories in patients with type 2 diabetes.
Design, Setting, And Participants: This retrospective cohort study used the Chang Gung Research Database, a clinical dataset covering multiple hospitals in Taiwan.
Cell Mol Biol (Noisy-le-grand)
September 2025
M-DT1, Roquefort-les Pins, France.
To date, the closed-loop system represents the best commercialized management of type 1 diabetes. However, mealtimes still require carbohydrate estimation and are often associated with postprandial hyperglycemia which may contribute to poor metabolic control and long -term complications. A multicentre, prospective, non-interventional clinical trial was designed to determine the effectiveness of a novel algorithm to predict changes in blood glucose levels two hours after a usual meal.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
de Duve Institute, Faculté de Pharmacie et des Sciences Biomédicales, Université Catholique de Louvain, Brussels, Belgium.
The understanding of the conformational events occurring through the Insulin-like Receptors (ILRs) upon binding of their cognate hormones is very advanced, thanks to multidisciplinary efforts and breakthroughs, from molecular/cell biology to structural studies. However, the full length structures of this class of Tyrosine Kinase (TK) receptors are still not available. This is due to fundamental methodological constraints: a need for lipid micelles or nanodiscs required for the stabilisation of the full-length single receptor molecule.
View Article and Find Full Text PDFNutr Clin Pract
September 2025
School of Biological, Health and Sports Sciences, Technological University Dublin, Dublin, Ireland.
Background: Esophagectomy causes anatomical changes that can lead to rapid food transit and reactive hypoglycemia (RH). Patients are advised on eating patterns postesophagectomy to prevent RH, but its true incidence and the impact of dietary recommendations remain under-researched.
Materials And Methods: Individuals >12 months postesophagectomy were recruited from the National Centre for Oesophageal and Gastric Cancer at St James's Hospital in Dublin, Ireland.
Diab Vasc Dis Res
September 2025
Mary and Steve Wen Cardiovascular Division, School of Medicine, University of California, Irvine, CA, USA.
BackgroundThe SUSTAIN-6 trial showed the cardiovascular disease (CVD) benefits of semaglutide among patients with type 2 diabetes mellitus (T2DM). We estimated the US population eligibility and preventable CVD events from semaglutide.MethodsUS adults with T2DM were selected from the National Health and Nutrition Examination Survey 2011-2020 based on SUSTAIN-6 eligibility criteria.
View Article and Find Full Text PDF